Our new head of technology Ari Gesher talked about the lab of the future with R&D - Research & Development World. He is combining lessons from software development with the power of organoid technology to automate the lab and free biologists to design experiments at a scale never seen before.
Parallel Bio
生物技术
Cambridge，Massachusetts 1,294 位关注者
Using the immune system to cure disease.
关于我们
Parallel Bio created a human 'immune system in a dish' to discover drugs and immunotherapies more likely to work in patients.
- 网站
-
https://www.parallel.bio
Parallel Bio的外部链接
- 所属行业
- 生物技术
- 规模
- 2-10 人
- 总部
- Cambridge，Massachusetts
- 类型
- 私人持股
地点
-
主要
获取路线
750 Main St
US，Massachusetts，Cambridge，02139
Parallel Bio员工
-
Joshua Goldenberg
Force multiplier for startups.
-
Ari Gesher
Deep Tech Architect & Builder. I put the computing into the industrialization of science.
-
Chris Paschall PhD MBA
Pharma & Biotech | Business Development | Alliance Management | Licensing | Intellectual Property | Early-Stage Scouting | Transactions | External…
-
Mary Clare McFadden
ex- BCG & Korn Ferry | Operations, Strategy and Internal TA for start ups & PE backed companies
动态
-
A warm welcome?to Ari Gesher, our first head of technology! Ari is bringing his cutting-edge experience in software and deep tech to Parallel Bio and advancing our immune organoid platform. Together, we'll be able to treat human disease better, faster, and cheaper than ever before.
Parallel Bio Appoints Deep Tech Innovator Ari Gesher as Head of Technology
businesswire.com
-
We are thrilled to see our Clinical Trial in a Dish featured in?Fierce Biotech. As our co-founder Juliana L. Hilliard said this; "marks the first step toward human models that can take the place of animals and people to uncover drugs that work safely and effectively from the start.”
Parallel Bio serves up ‘clinical trial in a dish’ as animal model alternative
fiercebiotech.com
-
We’re proud to announce our Clinical Trial in a Dish - where drugs are proven to work in humans before they ever reach a real patient. Clinical Trial in a Dish studies the safety and efficacy of new drugs entirely in human models using immune organoids at population scale. Pharma partners are already using our alternative to animal models to test more than 20 drug candidates.? By starting with human models that work, we aim to flip the 95% drug failure rate to a 95% success rate and bring approved treatments to patients faster than ever before.
Parallel Bio Launches Clinical Trial in a Dish to Speed Drug Discovery
businesswire.com
-
We're #hiring a new Senior Scientist in Cambridge, Massachusetts! Apply today or share this post with your network.